Iron-based nanoscale coordination polymers synergistically induce immunogenic ferroptosis by blocking dihydrofolate reductase for cancer immunotherapy

Biomaterials. 2022 Sep:288:121724. doi: 10.1016/j.biomaterials.2022.121724. Epub 2022 Aug 18.

Abstract

Iron is indispensable for cancer cell survival and cancer cells are more vulnerable to ferroptosis than normal cells. Ferroptosis holds promise for overcoming chemoresistance and inducing tumor immunogenic cell death, which offers new possibilities for cancer immunotherapy. However, the prevalence of immunogenic ferroptosis in cancer cells is diminished because of the high levels of reducing substances within tumor microenvironments. Ferroptosis-needed iron is overdose for livings, which is also an obstacle for effective immune responses. In this study, we construct self-assembled carrier-free nanoscale coordination polymers based on iron and methotrexate (MFe-NCPs). The low-dose-iron-induced immunogenic ferroptosis is obviously enhanced by methotrexate via inhibiting dihydrofolate reductase and abating substance reduction, respectively. Of note, MFe-NCPs sequentially promoted antigen presentation, immune activation, T cell infiltration and boosted the therapeutic effect of immune checkpoint blockade therapy.

Keywords: Dihydrofolate reductase; Immunogenic ferroptosis; Methotrexate; Nanoscale coordination polymers; Tetrahydrobiopterin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ferroptosis* / drug effects
  • Humans
  • Immunotherapy / methods
  • Iron* / pharmacology
  • Methotrexate / pharmacology
  • Methotrexate / therapeutic use
  • Neoplasms* / drug therapy
  • Polymers / pharmacology
  • Tetrahydrofolate Dehydrogenase / drug effects
  • Tumor Microenvironment

Substances

  • Polymers
  • Iron
  • Tetrahydrofolate Dehydrogenase
  • Methotrexate